GT Biopharma Inc. (GTBP)
2.37
-0.01 (-0.42%)
At close: Mar 03, 2025, 3:59 PM
2.26
-4.64%
After-hours: Mar 03, 2025, 04:16 PM EST
No 1D chart data available
| Bid | 2.11 |
| Market Cap | 5.3M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -12.35M |
| EPS (ttm) | -7.39 |
| PE Ratio (ttm) | -0.32 |
| Forward PE | -0.19 |
| Analyst | Buy |
| Ask | 2.41 |
| Volume | 48,161 |
| Avg. Volume (20D) | 946,765 |
| Open | 2.40 |
| Previous Close | 2.38 |
| Day's Range | 2.34 - 2.41 |
| 52-Week Range | 1.72 - 10.66 |
| Beta | 0.59 |
About GTBP
GT Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology products based on its proprietary Tri-specific Killer Engager (TriKE) fusion protein immune cell engager technology platform. It develops GTB-3550, a single-chain tri-specific recombinant fusion protein conjugate that is in Phase I/II clinical trial for the treatment of myelodysplastic syndromes, refractory/relapsed ...
Industry Biotechnology
Sector Healthcare
IPO Date Mar 27, 2018
Employees 1
Stock Exchange NASDAQ
Ticker Symbol GTBP
Website https://www.gtbiopharma.com
Analyst Forecast
According to 1 analyst ratings, the average rating for GTBP stock is "Buy." The 12-month stock price forecast is $11, which is an increase of 364.14% from the latest price.
Buy 100.00%
Hold 0.00%
Sell 0.00%
1 week ago
+21.18%
GT Biopharma shares are trading higher after the c...
Unlock content with
Pro Subscription
2 months ago
+60.57%
GT Biopharma shares are trading higher. Roth MKM initiated coverage on the stock with a Buy rating and set its price target at $11.
